Dosimeters Market Reaches USD 13.1 Billion in 2026, Driven by Growing Adoption of Radiotherapy, Nuclear Medicine, and Occupational Radiation Monitoring - Coherent Market Insights

Technological Advancements in Radiation Detection and Increasing Radiation-Safety Requirements to Drive Dosimeters Market to USD 18.4 Billion by 2033 at 7.1% CAGR – Coherent Market Insights

Global Dosimeters Market, by Product Type (Active Dosimeters and Passive Dosimeters), by Modality (Portable Dosimeters (Wearable (Collar Level, Chest Level, Waist Level, Wrist Level, and Finger Level (i.e. Ring Dosimeters)), and Non-wearable), and Bench-top Dosimeters), by End User (Hospitals, Ambulatory Care Centers, Research Institutes, and Healthcare Companies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 13.1 Bn in 2026, and is projected to exhibit a CAGR of 7.1% over the forecast period (2026 – 2033).

Increasing adoption of radiation emitting diagnostic tools and therapies is expected to drive the dosimeters market growth in near future. Increasing adaption of diagnosis tools such as CT scan and MRI by hospitals and ambulatory care centers is expected to increase the demand for the dosimeters for the professionals working with these tools. Hence, increasing installments of these devices is expected to increase demand for dosimeters and drive the global dosimeters market growth in near future.

Market Opportunity

The increasing adoption of adaptive radiotherapy, theranostics and personalized cancer treatment presents a significant growth opportunity for the dosimeters market. Healthcare providers require advanced dosimeters and dose-verification systems capable of measuring patient-specific radiation exposure, detecting treatment-delivery deviations and supporting faster quality-assurance workflows. This creates opportunities for manufacturers to develop high-resolution detectors, real-time in-vivo dosimeters and AI-enabled dosimetry platforms for radiotherapy and nuclear medicine.

For instance, in February 2026, Sun Nuclear, a company that provides integrated, independent, Quality Management (QM) solutions for Radiation Therapy and Diagnostic Imaging centers globally introduced the Daily QA 4 Pro device, which combines dosimetry, imaging and positioning checks in a single system to enable faster setup and more consistent radiotherapy quality-assurance workflows. In June 2026, DOSIsoft also received U.S. FDA 510(k) clearance for ThinkQA 3.0, a web-based patient-specific dose-verification platform supporting online adaptive radiotherapy using CT-Linacs and MR-Linacs. These developments demonstrate increasing commercial opportunities for automated and personalized dosimetry solutions in cancer-care facilities. (Source: Mirion; DOSIsoft)

To know the latest trends and insights prevalent in the Dosimeters Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/dosimeters-market-1918

Increasing adoption of radiotherapy and nuclear medicine for cancer diagnosis and treatment is strengthening demand for personal and clinical dosimeters used for occupational radiation monitoring, treatment-dose verification, and healthcare-worker safety. The growing cancer burden is also increasing the number of patients requiring radiation-based diagnostic and therapeutic procedures. For instance, in April 2026, Cancer Research UK reported that more than 403,000 people are diagnosed with cancer annually in the U.K., equivalent to approximately 1,100 new diagnoses every day. Furthermore, in June 2026, NHS England announced that thousands of eligible men with localized prostate cancer would receive stereotactic ablative radiotherapy, which delivers treatment in five doses within a fortnight, compared with at least 20 doses of conventional external-beam radiotherapy. The expansion of such precision-radiotherapy programs is expected to increase requirements for accurate radiation-dose measurement and personnel monitoring, thereby supporting growth of the dosimeters market. (Source: Cancer Research UK; NHS)

Market Trends

• AI and Automation are Transforming Radiotherapy Dosimetry

Artificial intelligence and automated dose-verification systems are becoming important components of radiotherapy quality assurance. These technologies reduce manual calculations, accelerate machine testing and identify potential dose-delivery errors before patient treatment. In February 2026, Sun Nuclear introduced the Daily QA 4 Pro device at QADS 2026. The system combines dosimetry, imaging and positioning checks in one device, enabling quicker setup, fewer treatment-room entries and more consistent workflows. The event also highlighted the expansion of AI-enabled solutions for machine QA, patient-specific QA and in-vivo dosimetry.

• Personalized Dosimetry is Expanding in Theranostics

The growth of radiopharmaceutical therapies is increasing demand for software that calculates absorbed radiation doses for individual organs, tumors and healthy tissues. In May 2026, DOSIsoft launched DOSIsoft Theranostics, a dedicated business focused on developing personalized nuclear-medicine and theranostics software for wider routine clinical adoption. The trend is also reflected in the IAEA’s IDOS 2026 program, which covers dosimetry for new radiopharmaceuticals, alpha-emitting therapies, PET/CT, SPECT/CT and targeted radiopharmaceutical treatments. These developments are shifting nuclear-medicine dosimetry from standardized administered activity toward individualized treatment planning.

• Stricter Regulations are Strengthening Personnel-Monitoring Compliance

Regulatory authorities and healthcare institutions are placing greater emphasis on consistent dosimeter use, exposure documentation and long-term dose-history management. A peer-reviewed Japanese study published in February 2026 found that the primary personal-dosimeter wearing rate among medical radiation workers increased from 64.6% to 77.9% following a reduction in the occupational eye-lens dose limit. Separately, the U.S. Department of Energy published its latest occupational-radiation-exposure report in February 2026 and continued maintaining its Radiation Exposure Monitoring System, which contains more than four million exposure records. These measures support sustained demand for accredited dosimetry services and digital reporting systems.

• Greater Focus on International Standards and Dosimetry Quality Assurance

Standardization is becoming increasingly important as advanced radiotherapy, proton therapy, diagnostic imaging and nuclear medicine require comparable dose measurements across equipment and clinical facilities. The IAEA scheduled the International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry for October 5–9, 2026. The event focuses on radiation metrology, reference dosimetry, independent audits, dose-management systems and quality assurance across radiotherapy, interventional radiology and nuclear medicine. This international focus is expected to increase demand for calibrated instruments, traceable dosimeters, audit services and standardized dose-management platforms. (Source: IAEA)

Key Takeaways of the Dosimeters Market

• The global dosimeters market is expected to exhibit a CAGR of 7.1% over the forecast period (2026 – 2033), owing to frequent product launches, approval, and robust pipeline of novel biopharmaceutical products
• North America held the dominant position in the global dosimeters market and is expected to retain its dominance over the forecast period (2026 – 2033), owing to presence of major market players and product development and innovations in the region. For instance, Thermo Fisher Scientific, Mirion Technologies, Inc., PRS Dosimetry, Radiation Detection Company, and Landauer, Inc., are U.S.-based key players who provide wide range of dosimeters in the region.
• Asia Pacific is expected to witness significant growth over the forecast period, supported by the introduction of technologically advanced dosimeters in countries such as Japan and China. For instance, in March 2026, Japan-based Aloka Co., Ltd. developed the new MyDose Mini PDM-700 Series of personal dosimeters with Bluetooth connectivity. The series includes dedicated models for measuring gamma rays, X-rays and neutron radiation and enables more convenient, real-time management of occupational radiation-exposure data in hospitals, universities, research institutes and nuclear facilities. The commercialization of such connected personal dosimeters is expected to strengthen radiation-monitoring capabilities and support growth of the dosimeters market in Asia Pacific.
• Major players operating in the dosimeters market include Thermo Fisher Scientific Inc., PRS Dosimetry, Mirion Technologies Inc., Landauer Inc., Polimaster Ltd., Radiation Detection Company Inc., Sierra Radiation Dosimetry Services Inc., Tracerco Limited, Unfors RaySafe AB, and PTW Frieburg GmbH

Key Development

• In May 2026, DOSIsoft launched DOSIsoft Theranostics, a dedicated entity focused on accelerating software innovation for personalized nuclear medicine and theranostics. The new organization will operate independently, supporting clinical and industrial partners through vendor-neutral software, strategic partnerships, and long-term investment. Its FDA-cleared and CE-marked PLANET platform enables personalized, voxel-based dosimetry across diverse workflows, helping expand routine clinical adoption of targeted radiopharmaceutical diagnosis and treatment worldwide, while improving cancer treatment precision.